A citation-based method for searching scientific literature

Nulgumnalli Manjunathaiah Raghavendra, Divya Pingili, Sundeep Kadasi, Akhila Mettu, S V U M Prasad. Eur J Med Chem 2018
Times Cited: 93







List of co-cited articles
514 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Designing multi-targeted agents: An emerging anticancer drug discovery paradigm.
Rong-Geng Fu, Yuan Sun, Wen-Bing Sheng, Duan-Fang Liao. Eur J Med Chem 2017
85
20

A perspective on multi-target drug discovery and design for complex diseases.
Rona R Ramsay, Marija R Popovic-Nikolic, Katarina Nikolic, Elisa Uliassi, Maria Laura Bolognesi. Clin Transl Med 2018
304
15

Polypharmacology: challenges and opportunities in drug discovery.
Andrew Anighoro, Jürgen Bajorath, Giulio Rastelli. J Med Chem 2014
557
15


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
10

Designed multiple ligands. An emerging drug discovery paradigm.
Richard Morphy, Zoran Rankovic. J Med Chem 2005
841
8

Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
Jie Zang, Xuewu Liang, Yongxue Huang, Yuping Jia, Xiaoyang Li, Wenfang Xu, C James Chou, Yingjie Zhang. J Med Chem 2018
56
14

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.
Garrett M Morris, Ruth Huey, William Lindstrom, Michel F Sanner, Richard K Belew, David S Goodsell, Arthur J Olson. J Comput Chem 2009
7



UCSF Chimera--a visualization system for exploratory research and analysis.
Eric F Pettersen, Thomas D Goddard, Conrad C Huang, Gregory S Couch, Daniel M Greenblatt, Elaine C Meng, Thomas E Ferrin. J Comput Chem 2004
6


The Protein Data Bank.
H M Berman, J Westbrook, Z Feng, G Gilliland, T N Bhat, H Weissig, I N Shindyalov, P E Bourne. Nucleic Acids Res 2000
6



Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
Lianbin Yao, Nurulhuda Mustafa, Eng Chong Tan, Anders Poulsen, Prachi Singh, Minh-Dao Duong-Thi, Jeannie X T Lee, Pondy Murugappan Ramanujulu, Wee Joo Chng, Jeffrey J Y Yen,[...]. J Med Chem 2017
65
9

Molecular hybridization: a useful tool in the design of new drug prototypes.
Cláudio Viegas-Junior, Amanda Danuello, Vanderlan da Silva Bolzani, Eliezer J Barreiro, Carlos Alberto Manssour Fraga. Curr Med Chem 2007
485
5

From magic bullets to designed multiple ligands.
Richard Morphy, Corinne Kay, Zoran Rankovic. Drug Discov Today 2004
522
5

Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening.
Thomas A Halgren, Robert B Murphy, Richard A Friesner, Hege S Beard, Leah L Frye, W Thomas Pollard, Jay L Banks. J Med Chem 2004
5

Multi-Targeted Anticancer Agents.
Wei Zheng, Yao Zhao, Qun Luo, Yang Zhang, Kui Wu, Fuyi Wang. Curr Top Med Chem 2017
45
11

Combination therapy in combating cancer.
Reza Bayat Mokhtari, Tina S Homayouni, Narges Baluch, Evgeniya Morgatskaya, Sushil Kumar, Bikul Das, Herman Yeger. Oncotarget 2017
787
5

Histone Deacetylase Inhibitors as Anticancer Drugs.
Tomas Eckschlager, Johana Plch, Marie Stiborova, Jan Hrabeta. Int J Mol Sci 2017
616
5

Molecular properties that influence the oral bioavailability of drug candidates.
Daniel F Veber, Stephen R Johnson, Hung-Yuan Cheng, Brian R Smith, Keith W Ward, Kenneth D Kopple. J Med Chem 2002
5

Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
Tingting Liu, Yichao Wan, Yuliang Xiao, Chengcai Xia, Guiyun Duan. J Med Chem 2020
49
10

New colorimetric cytotoxicity assay for anticancer-drug screening.
P Skehan, R Storeng, D Scudiero, A Monks, J McMahon, D Vistica, J T Warren, H Bokesch, S Kenney, M R Boyd. J Natl Cancer Inst 1990
4

Can we rationally design promiscuous drugs?
Andrew L Hopkins, Jonathan S Mason, John P Overington. Curr Opin Struct Biol 2006
341
4

Multi-target therapeutics: when the whole is greater than the sum of the parts.
Grant R Zimmermann, Joseph Lehár, Curtis T Keith. Drug Discov Today 2007
702
4

Polypharmacology - foe or friend?
Jens-Uwe Peters. J Med Chem 2013
278
4


Multitarget drugs: the present and the future of cancer therapy.
Annalisa Petrelli, Giorgio Valabrega. Expert Opin Pharmacother 2009
53
7


Multi-target-directed ligands to combat neurodegenerative diseases.
Andrea Cavalli, Maria Laura Bolognesi, Anna Minarini, Michela Rosini, Vincenzo Tumiatti, Maurizio Recanatini, Carlo Melchiorre. J Med Chem 2008
760
4

Targeting the cancer kinome through polypharmacology.
Zachary A Knight, Henry Lin, Kevan M Shokat. Nat Rev Cancer 2010
500
4

Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.
Richard A Friesner, Jay L Banks, Robert B Murphy, Thomas A Halgren, Jasna J Klicic, Daniel T Mainz, Matthew P Repasky, Eric H Knoll, Mee Shelley, Jason K Perry,[...]. J Med Chem 2004
4

Open Babel: An open chemical toolbox.
Noel M O'Boyle, Michael Banck, Craig A James, Chris Morley, Tim Vandermeersch, Geoffrey R Hutchison. J Cheminform 2011
4

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Paul T C Wan, Mathew J Garnett, S Mark Roe, Sharlene Lee, Dan Niculescu-Duvaz, Valerie M Good, C Michael Jones, Christopher J Marshall, Caroline J Springer, David Barford,[...]. Cell 2004
4

Kinase-targeted cancer therapies: progress, challenges and future directions.
Khushwant S Bhullar, Naiara Orrego Lagarón, Eileen M McGowan, Indu Parmar, Amitabh Jha, Basil P Hubbard, H P Vasantha Rupasinghe. Mol Cancer 2018
464
4


Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Guoqiang Dong, Wei Chen, Xia Wang, Xinglin Yang, Tianying Xu, Pei Wang, Wannian Zhang, Yu Rao, Chaoyu Miao, Chunquan Sheng. J Med Chem 2017
62
6

Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation.
Neha Upadhyay, Kalpana Tilekar, Niklas Jänsch, Markus Schweipert, Jessica D Hess, Luca Henze Macias, Piotr Mrowka, Renato J Aguilera, Jun-Yong Choe, Franz-Josef Meyer-Almes,[...]. Bioorg Chem 2020
15
26

The enzyme activity of histone deacetylase 8 is modulated by a redox-switch.
Niklas Jänsch, Christian Meyners, Marius Muth, Aleksandra Kopranovic, Olaf Witt, Ina Oehme, Franz-Josef Meyer-Almes. Redox Biol 2019
23
17

Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms.
Junting Zhou, Xueyang Jiang, Siyu He, Hongli Jiang, Feng Feng, Wenyuan Liu, Wei Qu, Haopeng Sun. J Med Chem 2019
98
4

The efficiency of multi-target drugs: the network approach might help drug design.
Péter Csermely, Vilmos Agoston, Sándor Pongor. Trends Pharmacol Sci 2005
529
3

Features and development of Coot.
P Emsley, B Lohkamp, W G Scott, K Cowtan. Acta Crystallogr D Biol Crystallogr 2010
3


Computational Multitarget Drug Design.
Weilin Zhang, Jianfeng Pei, Luhua Lai. J Chem Inf Model 2017
76
3

Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs.
Lin Tao, Feng Zhu, Feng Xu, Zhe Chen, Yu Yang Jiang, Yu Zong Chen. Pharmacol Res 2015
40
7

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia.
Bryan L Roth, Douglas J Sheffler, Wesley K Kroeze. Nat Rev Drug Discov 2004
829
3

The physicochemical challenges of designing multiple ligands.
Richard Morphy, Zoran Rankovic. J Med Chem 2006
155
3

Multitarget ligands in antibacterial research: progress and opportunities.
Stephen P East, Lynn L Silver. Expert Opin Drug Discov 2013
44
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.